Vireo Growth (VREOF) Other Non-Current Assets (2020 - 2026)
Vireo Growth (VREOF) posted Other Non-Current Assets of $4.4 million for Q1 2026, little changed sequentially from $4.4 million in Q4 2025, and up 944.53% YoY from $421244.0 in Q1 2025.
Vireo Growth (VREOF) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Vireo Growth has reported Other Non-Current Assets for 7 years, with the latest figure at $4.4 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 944.53% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 944.53% YoY) and the FY2025 annual result came in at $4.4 million, up 944.53% from the prior year.
- Other Non-Current Assets held at $4.4 million in Q1 2026 per VREOF's latest filing, from $4.4 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $4.4 million in Q4 2025 and troughed at $328166.0 in Q2 2025.
- A 5-year average of $1.4 million and a median of $533745.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets tumbled 83.41% in 2023, then soared 944.53% in 2025.
- Over 5 years, Other Non-Current Assets stood at $2.3 million in 2022, then sank by 83.41% to $383645.0 in 2023, then advanced by 9.8% to $421244.0 in 2024, then jumped by 944.53% to $4.4 million in 2025, then changed by 0.0% to $4.4 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $4.4 million, $4.4 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 13.00 Mn |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn | 4.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.40 Mn |
| Dec 31, 2025 | 4.40 Mn |
| Sep 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | 328,166.00 |
| Mar 31, 2025 | 421,244.00 |
| Dec 31, 2024 | 421,244.00 |
| Sep 30, 2024 | 533,745.00 |
| Jun 30, 2024 | 533,745.00 |
| Mar 31, 2024 | 533,745.00 |
| Dec 31, 2023 | 383,645.00 |
| Sep 30, 2023 | 383,645.00 |
| Jun 30, 2023 | 383,645.00 |
| Mar 31, 2023 | 593,812.00 |
| Dec 31, 2022 | 2.31 Mn |
| Sep 30, 2022 | 2.18 Mn |
| Jun 30, 2022 | 2.12 Mn |
| Mar 31, 2022 | 1.99 Mn |
| Dec 31, 2021 | 1.72 Mn |
| Sep 30, 2021 | 1.34 Mn |
| Jun 30, 2021 | 1.41 Mn |